Palma-Carlos A G, Palma-Carlos M L
Cent. Hemat. Immunol. (INIC), Immunology Institute, Lisbon-Portugal.
Allerg Immunol (Paris). 1990 May;22(5):179, 181-5.
The recent advances in immunology have opened the way for new therapeutic approaches aiming at modulating the various components of the immune system in man. Lyophilized bacterial lysate were studied in a large number of models and found, when given orally, or by aerosol to induce specific and non specific responses. They stimulate the systemic and local immune response and activates the macrophages which play a key role in the immune system, modulates the level of serum immunoglobulins and potentiates the lymphocyte response to PHA and other mitogens. Based on these data a trial was conducted on 332 patients with or without bronchial asthma and recurrent respiratory tract infections. These patients have been observed during 2 years, the first year without therapy the second with bacterial lysates. The evolution during these 2 winters have been analysed by a score method. Improvements were recorded in about 2/3 of the cases and the number of infections were reduced from 2.14/patients to 1.08/patient (p less than 0.001). Bacterial lysates could be considered as an effective therapy or a preventive measure for respiratory tract infections in patients with or without bronchial asthma. The levels of serum immunoglobulins IgG, IgA, IgM and IgE have been studied before and after oral immunotherapy with a bacterial lysate in 88 patients bronchial asthma, repeated respiratory infection, and 12 cases of IgA deficiency. A significant increase in IgA has been observed in nine patients presenting initially a decreased IgA serum level. In three patients without response to the standard treatment an increase in IgA was achieved by increasing the dosage of oral bacterial lysate.(ABSTRACT TRUNCATED AT 250 WORDS)
免疫学的最新进展为旨在调节人体免疫系统各个组成部分的新治疗方法开辟了道路。冻干细菌裂解物在大量模型中进行了研究,发现口服或通过气溶胶给药时可诱导特异性和非特异性反应。它们刺激全身和局部免疫反应,激活在免疫系统中起关键作用的巨噬细胞,调节血清免疫球蛋白水平,并增强淋巴细胞对PHA和其他有丝分裂原的反应。基于这些数据,对332例有或无支气管哮喘及反复呼吸道感染的患者进行了一项试验。对这些患者观察了两年,第一年未进行治疗,第二年使用细菌裂解物。通过评分方法分析了这两个冬季的病情变化。约2/3的病例有改善,感染次数从每位患者2.14次减少到1.08次(p<0.001)。细菌裂解物可被视为有或无支气管哮喘患者呼吸道感染的有效治疗方法或预防措施。对88例支气管哮喘、反复呼吸道感染患者以及12例IgA缺乏症患者在口服细菌裂解物免疫治疗前后的血清免疫球蛋白IgG、IgA、IgM和IgE水平进行了研究。在9例最初血清IgA水平降低的患者中观察到IgA显著升高。在3例对标准治疗无反应的患者中,通过增加口服细菌裂解物的剂量使IgA升高。(摘要截短于250字)